Novel medical drink/food for dietary prevention of dementia
Proof of concept
Numerous proof-of-concept studies have been performed
Pharmaceutical : Pharmaceutical product is the nasal spray. It is novel composition of 7% Mitocholine and low deuterium water as excipient.
Non-toxic intranasal spray
It has been proven that Mitocholine is effective in animal models of acute and chronic cerebral hypoperfusion as antihypoxant, antiischemic agent and cognition enhancer (see Proof of Concept studies in animals). Relevant indications are vascular dementia, stroke, transient ischemic attack, subarachnoid hemorrhage, brain surgery. Mitocholine is effective in animal models of cognitive deficits caused by chronological aging, chronic cerebral ischemia, beta-amyloid toxicity, scopolamine (used as a blocker of cholinergic transmission) and chronic stress (see Proof of Concept studies in animals).
Relevant indications are mild cognitive impairments, vascular dementia cognitive complications of stroke, Alzheimer’s disease, cognitive problems associated with depression.
It has been proven that Mitocholine is effective in animal models of depression and anxiety caused by chronic stress (see Proof of Concept studies in animals). Relevant indications are depression, anxiety, burnout and psychological distress.
Mitocholine in low deuterium aqueous solution is uniquely positioned for development as CNS drug with antihypoxic, antiischemic, antiamnestic, antidepressive, and antianxiety drug (anti-ageing drug).
Injectable Mitocholine is currently undergoing clinical trials in Russia.
Oral route of administration can be preferred for medical food/supplement regulation.